Chronic obstructive pulmonary disease (COPD) will soon become the third leading cause of death in the world. COPD is caused by multiple factors including environmental exposures, infections, inflammation, and genetic predisposition. Several lines of investigation have indicated that, in advanced disease, increased bacterial colonization leads to airway inflammation and accelerated airway obstruction. However, in early COPD, culture-dependent techniques commonly failed to isolate bacteria. Thus, the role of microbes in COPD has been difficult to study. We hypothesize that microbes are part of the pathogenesis of early COPD, contributing to inflammatory processes. This proposal will use culture independent techniques to evaluate the contribution of the microbiome to airway inflammation in early COPD. It will also investigate the microbial genomic potential (metagenome) and metabolic profile (metabolome) to better understand functional aspects of the lung microbiome.
Aim 1 will assess lung microbiome and inflammation in smokers with and without COPD. We will perform research bronchoscopy in 48 subjects with mild-moderate COPD and 48 matched smoker controls to measure lung inflammation with multiplexed cytokine assays of bronchoalveolar lavage and lower airway bacteria by 16S rRNA gene sequencing.
Aim 2 will investigate active bacterial metabolic pathways in the lower airways using metagenomics and metabolomics by using the samples obtained in AIM 1. We will test whether differences in genomic potential of the lower airway microbiome accounts for variation in the lung metabolome. Presence of correlation between operons encoding synthetic pathways and the metabolic products of those pathways would support that the lung microbiome is metabolically active, thus composed by live microorganisms.
Aim 3 will assess relationships among different inter-omic datasets (microbiome, metagenome, metabolome and host immune responses) in COPD and controls with the goal of integrating information from vastly different platforms to achieve a multidimensional model of disease. Under the mentorship of Drs. Blaser, Weiden and with the collaboration of Dr. Virgin, Fiehn, and Clemente this research plan will serve as the foundation of a training plan that uses state-of-the-art molecular and bio-informatic methods to improve our understanding of complex bacterial community networks and their association with host immune response in COPD.

Public Health Relevance

Chronic obstructive pulmonary disease (COPD) will become the third leading cause of death in the world by 2020. There are no pharmacological therapies today that will prevent disease progression or reduce mortality once COPD is established. In advanced disease, increased bacterial colonization of the airways has been associated with disease progression. However, the study of the role of microbes in the initiation of the inflammation and consequent lung destruction has been limited by reliance on culture methods. This investigation will use novel culture-independent methods to explore the contribution of microbes to airway inflammation in early disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Gondre-Lewis, Timothy A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Gregory, Ann C; Sullivan, Matthew B; Segal, Leopoldo N et al. (2018) Smoking is associated with quantifiable differences in the human lung DNA virome and metabolome. Respir Res 19:174
Wu, Benjamin G; Segal, Leopoldo N (2018) The Road to Precision Medicine in Chronic Obstructive Pulmonary Disease: Squeezing More Out of Chest Computed Tomography Scans. Ann Am Thorac Soc 15:428-429
Segal, Leopoldo N; Martinez, Fernando J (2018) Chronic obstructive pulmonary disease subpopulations and phenotyping. J Allergy Clin Immunol 141:1961-1971
Martinez, Fernando J; Han, MeiLan K; Allinson, James P et al. (2018) At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1540-1551
Manasson, Julia; Shen, Nan; Garcia Ferrer, Helga R et al. (2018) Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis. Arthritis Rheumatol 70:242-254
Wu, Benjamin G; Segal, Leopoldo N (2018) The Lung Microbiome and Its Role in Pneumonia. Clin Chest Med 39:677-689
Tsay, Jun-Chieh J; Wu, Benjamin G; Badri, Michelle H et al. (2018) Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 198:1188-1198
Wu, Benjamin G; Segal, Leopoldo N (2017) Lung Microbiota and Its Impact on the Mucosal Immune Phenotype. Microbiol Spectr 5:
Segal, Leopoldo N; Clemente, Jose C; Wu, Benjamin G et al. (2017) Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax 72:13-22
Wang, Jing; Lesko, Melissa; Badri, Michelle H et al. (2017) Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-?. ERJ Open Res 3:

Showing the most recent 10 out of 20 publications